HSR21-057: Cost-Effectiveness of Cemiplimab vs Pembrolizumab for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) and Programmed Death-Ligand 1 (PD-L1) Expression ≥50% in the US

View More View Less
  • 1 Regeneron Pharmaceuticals, Inc., Tarrytown, NY
  • | 2 Precision HEOR, London, UK
  • | 3 Sanofi, Reading, UK
  • | 4 Sanofi, Chilly-Mazarin, France
  • | 5 Precision HEOR, Vancouver, BC, Canada
  • | 6 Precision HEOR, Boston, MA
Restricted access

Corresponding Author: Andreas Kuznik, PhD